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Background: Endoscopic treatments for early esophageal squamous cell carcinoma and the esophageal neoplasm
are two types: endoscopic resection (ER) and ablation. Resection enables evaluation of the lesion in the ER specimens,
while ablation cannot. We sought to establish a pre-ER evaluated system with a diagnostic and staging accuracy similar
to ER for the development of ablation therapy.
Methods: In our study, we collected data pertaining to early esophageal cancer and esophageal neoplasm treated
with ER, analyzed the pre- and post-ER data of the lesions and evaluated the diagnostic accuracy of pre-ER system
compared with the gold standard.
Results: The diagnostic accuracy rate was 91% based on the pre-ER system compared with the gold standard, and
93% based on the ER diagnosis. The AUC of the pre-ER system was 0.964, while the ER examination was 0.971.
Conclusion: These results suggest that the accuracy of pre-ER system was comparable to ER. The pre-ER system enables
prediction of histological diagnosis and stage of the lesions, and the choice of treatment for superficial esophageal
neoplasm.
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Endoscopic resection (ER), indicated for the treatment of
superficial (early) gastroesophageal precursor, is also a good
diagnostic approach. According to the 2010 National
Comprehensive Cancer Network (NCCN) Clinical Practice
Guidelines in Oncology-Esophageal Cancer [1], esophagec-
tomy, endoscopic resection (ER) or ablation is indicated for
Tis or T1a tumors. ER specimens are used to accur-
ately determine the histopathological diagnosis as well
as the depth of tumor invasion in superficial lesions before
esophagectomy. Indications for ER treatment for esopha-
geal cancer include well and/or moderately differentiated
squamous cell carcinoma (SCC) confined to the lamina
propria without evidence of venous or lymphatic involve-
ment [2,3]. The updated Paris classification suggested that* Correspondence: wangguiq@126.com
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unless otherwise stated.the cut-off limit of esophageal superficial lesions for
endoscopic treatment was 200 μm invasive depth into the
submucosa, which was also supported by our previous
study [4].
The endoscopy treatment for the early esophageal cancer
and precursor, may be categorized into endoscopic resec-
tion(ER) with the samples and ablation therapies without
the samples. Determination of the depth of the lesions
without ER or esophagectomy should be further studied.
Although Endoscopic Ultrasonography (EUS) allows evalu-
ation of the invasive depth of the lesions and the biopsy
provides pathological diagnosis, appropriate treatment of
early esophageal cancer and precursor should also based
on endoscopic appearance and tumor grade. The pre-ER
diagnosis is based on a combination of endoscopy, macro-
scopic type (Paris classification), EUS and biopsy. Ablation
therapies such as radiofrequency ablation (RFA) and
photodynamic treatment (PDT) without ER specimens
after treatment constitute a meaningful approach.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of the pre-ER system and ER histological diagnosis with
the gold standard in superficial esophageal precursor and
evaluated the accuracies of the two approaches. In prac-
tice, ER histological diagnoses are not identical with true
diagnosis. Therefore, the gold standard adopted included




We retrospectively analyzed data of the early esophageal
cancer and precursor, which were treated with endoscopic
resection (ER) at the Department of Endoscopy, Cancer
Institute and Hospital, Chinese Academy of Medical
Science from January 2007 to March 2011. The indica-
tions for ER in our hospital include: (1) Endoscopic and
histological diagnosis of high-grade intraepithelial neoplasia
(HGIN, severe dysplasia) or early esophageal cancer (ESCC);
(2) low-grade intra-epithelial neoplasia (LGIN, mild dyspla-
sia) or middle-grade intraepithelial neoplasia (MGIN,
moderate dysplasia), while the diagnosis based on the
endoscopic examination was worse, as HGIN or ESCC;
(3) “superficial” (type 0-II) endoscopic appearance: “elevated”
(type 0-IIa), “flat” (type 0-IIb) or “depressed”(type 0-IIc). The
contraindications for ER included: (1) Lesions with positive
lymph node metastasis (N) or distant metastasis (M); (2)
EUS showing depth of invasion into the lower two-thirds of
the submucosa; (3) “protruding” (type 0-I) or “excavated”
(type 0-III) endoscopic appearance, according to the Paris
classification; (4) esophageal varices at the range of the le-
sion; and (5) uncontrolled coagulopathy with international
normalized ratio (INR) >2 or platelet count <75,000 per μL.
Procedures
The lesions diagnosed as esophageal precursor or early
cancer were stained with Lugol’s solution (if not allergic)
according to the endoscopic appearance. In our study, no
patients with allergy were seen, and all the lesions were
stained by the Lugol’s solution. The number of the forceps
biopsy was up to the length of the lesion, for instance,
lesion > 1 cm corresponded with the number of the bi-
opsy ≥ 2; the length > 2 cm, corresponded with number ≥
3, and the length > 3 cm, the number ≥ 4. The endoscopic
diagnosis was based on Lugol’s staining according to the
grade of the lesions [5]. If the diagnosis based on the
endoscopic images was HGIN or ESCC (that is grade I),
while the histopathological diagnosis based on the biopsy
was LGIN or MGIN, ER was performed after consultation
with patients. The macroscopic classification was based
on Paris endoscopic classification [2,3], classified as 0-IIa,
0-IIb, 0-IIc. We used the Paris classification to distinguish
the lesions as invasive or non-invasive, to decide the appro-
priate therapeutic intervention. Endoscopic ultrasonography(EUS) and computed tomography (CT) were performed
before ER to confirm the depth and absence of metasta-
sis. Only lesions without metastasis were appropriate for
ER. If the lesions were located in the mucosa or the upper
one- third of the submucosa (sm1), the lesion was treated
with ER. If the lesions invaded the lower two-third of the
submucosa (sm2), surgery was indicated according to the
EUS diagnosis.
The ER includes the endoscopic mucosa resection (EMR)
with suction cap- and/or saline solution-assisted snare
resection techniques according to Haruhiro Inouen [6-8]
and multiband mucosectomy (MBM) [9].
Management of biopsy and ER specimens
Biopsy specimens were obtained from all unstained lesions
(USLs) using standard biopsy forceps. Biopsy specimens
were removed using a toothpick or other non-traumatic
technique and spread out flat on a gloved finger. Each spe-
cimen was separately attached to filter paper and fixed
immediately. The filter paper was later removed and the
tissue was dehydrated, and embedded perpendicularly in
paraffin.
Resection specimens were pinned onto the cork with
the luminal side facing up. Piecemeal resection specimens
were reconstructed after staining with Lugol’s solution.
Specimens were subsequently fixed in 10% buffered for-
malin, cut into 2 mm sections, dehydrated and embedded
perpendicularly in paraffin.
Slices were cut, mounted on glass slides and stained with
hematoxylin and eosin. All slides of the biopsy and the ER
specimens were reviewed independently by two expert
gastrointestinal pathologists (L.X. and N.L.). Discordant
cases were reviewed jointly until a consensus was reached.
The following parameters were evaluated for invasive
lesions: depth of invasion (stage), degree of differentiation
(grade), lymph-vascular infiltration, submucosal invasive
depth (distance from the bottom of muscularis mucosa to
the base of cancer nests) [4].
Diagnostic criteria
Endoscopic diagnosis was based on the criteria established
in esophageal cancer high-risk regions (Figure 1) [5]. After
staining with Lugol’s solution, the mucosa with USL turned
brown, defined as negative. Weak USL with indistinct
margins, defined as grade III, was usually LGIN. The
weak USL with clear margin defined as grade II, was
usually MGIN. HGIN or T1 lesions comprise distinct
USL with clear margin, defined as grade I, with or with-
out protruded or depressed lesions.
EUS diagnosis was based on the layers of esophagus,
to detect the invasive depth of the lesion into mucosa
or submucosa, for possible resection. The EUS with the
Sonoprobe System was used before ER to evaluate the
resected specimens histopathologically. We interpreted
Figure 1 Endoscopic images for the USL grade to diagnose the lesions. The normal staining: Normal mucosa is negative after staining, and
some very weak staining suggests esophagitis (a). The USL is weak and the margin of the USL is indistinct, defined as the grade III, which is usually the
mild dysplasia (b). The USL is weak while the margin clear, defined as grade II, which is usually moderate dysplasia (c). The USL is distinct with the margin
clear, defined as grade I, with or without protrude or depressed lesions, which is usually the severe dysplasia (Tis) or T1 (d).
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using 20-MHz probe.
The macroscopic classification was based on the Paris
endoscopic classification [2,3], classified as 0-IIa, 0-IIb, 0-
IIc, to distinguish the invasive from non-invasive lesions.
The Paris classification dictated the choice of the ER.
Pathological diagnosis was based on a three-tier classi-
fication of squamous IN: LGIN, confined to the lowest
third of the epithelium; MGIN, the lower two-thirds and
HGIN, IN including the whole epithelium.
The pre-ER diagnosis was based on the worst possible
diagnostic outcome among the endoscopic examination,
the Paris classification and the biopsy histopathological
diagnosis. Such as, the lesion was 0-II according to the
Paris classification which was the indication for the ER.
If the diagnosis based on the biopsy was HGIN, while
endoscopic diagnosis after the lugo’s staining as the MGIN,
the pre-ER diagnosis was HGIN with the EUS no invasion
to submucosa. If the diagnosis based on the biopsy was
MGIN, while endoscopic diagnosis after the lugo’s staining
as the HGIN/ESCC, the pre-ER diagnosis was HGIN/
ESCC with the EUS no invasion to submucosa.
The gold standard for the lesion was based on a com-
bination of biopsy and ER, the worse one between these
two diagnose was the gold standard.
The under-diagnosed rate was determined, based on
the pre-ER systems or the ER diagnosis compared with
the gold standard. The accuracy rate was determined,
based on the pre-ER systems matching the gold standard.
The over-diagnosed rate was determined, based on the ex-
tent to which pre-ER systems or the ER diagnoses were
over-diagnosed compared with the gold standard.
Statistical analysis
The under-diagnosis, accuracy, and over-diagnosis rate
were calculated based on the number of the pre-ER as
numerator and the gold standard as denominator. The
under-diagnosis means the numerator was lesser than the
denominator, while the accuracy means the same diagnosis,
and the over-diagnosis means the numerator worse than
the denominator.The Receiver-Operating-Characteristic (ROC) curve was
used to evaluate the accuracy of the pre-ER system and
the ER diagnosis. The Area under each ROC (AUC) and
its 95% confidence were calculated. We used the Z-test to
examine the differences between the AUCs based on the
pre-ER diagnosis and ER diagnosis. All statistics were per-
formed using SPSS 17.0 for Windows.
Results
The data included 217 lesions of 203 cases, 150 males and
53 females, aged between 31 and 80 years, with the median
age 60 (Table 1). The esophageal cancer was mainly local-
ized to the middle esophagus (Table 1). The pre-ER system
included diagnosis based on biopsy, endoscopy, the Paris-
classification and the EUS. We first analyzed the diagnostic
accuracy of these modalities, individually. The under-
diagnosed rate, the accuracy rate and the over-diagnosed
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the gold standard, respectively. The rated of diagnosis based
on endoscopy were 49%, 46%, and 5%, compared with the
gold standard, respectively. The diagnostic rates following
the Paris-classification were 42%, 49%, 9%. Based on the
EUS, they were 26%, 57% and 17%, and based on the
pre-ER system 3%, 91% and 6%, respectively. The under-
diagnosed rate, the accuracy rate and the over-diagnosed
rate based on the ER-specimen were 7%, 93% and 0%,
compared with the gold standard, respectively (Table 2).
We calculated the AUC to quantify the consistency of
these diagnoses. The AUCs of the endoscopic diagnosis,Table 2 Summary of the comparison of the diagnoses based





LGIN 0 4 5
MGIN 0 11 7
HGIN 0 0 94
ESCC 0 0 0
EUS
Mucosa NA NA NA
Submucosa NA NA NA
Paris classification
0-IIa 0 17 48
0-IIb 0 14 89
0-IIc 0 0 0
Noninvasive 0 13 91
Invasive 0 2 15
Endoscopic diagnosis
LGIN 0 7 11
MGIN 0 3 27
HGIN 0 4 61
ESCC 0 1 7
ER diagnosis
LGIN 0 5 7
MGIN 0 10 20
HGIN 0 2 77
ESCC 0 0 2
Pre-ER diagnosis
LGIN 0 0 0
MGIN 0 9 6
HGIN 0 4 93
ESCC 0 2 7
LGIN: low-grade intra-epithelia neoplasia; MGIN: middle-grade intra-epithelia neopla
cell carcinoma.the Paris classification, the EUS and the biopsy were
0.738, 0.634, 0.683, and 0.696, respectively (P < 0.05). The
AUC of the pre-ER system combined with the endoscopic
diagnosis, Paris classification, EUS and biopsy was 0.963,
while the AUC of the diagnosis based on the ER speci-
mens was 0.971. No differences existed between these two
AUCs (u = 0.0405, u <1.96, P >0.05) (Figure 2).
The staging accuracy of the pre-system was evaluated
using the AUCs of the EUS and Paris classification. The
EUS was mainly used for evaluating the invasive depth,
while the Paris classification was used for evaluating the
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tion were 0.683 and 0.634, respectively (Figure 3).
This study was approved by the Ethics Committee of
Cancer Institute and Hospital, Chinese Academy of
Medical Sciences with the Approval Number 13-069/745
with the written consent exempted.
Discussion
Endoscopic resection (ER) is used to treat premalignant
and malignant lesions of the digestive tract. ER for squa-
mous superficial precursor of the esophagus was consid-
ered safe and efficient [10]. However, the pre-ER diagnosis
was as important as the ER diagnosis for treatment choice,
especially ablation therapies, such as the RFA and PDT.
It was demonstrated previously that the forceps bi-
opsy was sometimes inadequate for accurate histologicalFigure 2 The ROC of the Pre-ER system compared with the gold stan
the biopsy; Pre: the diagnosis based on the pre-endoscopic system).diagnosis [10,11], while the ER was relatively precise
(AUC = 0.971). Our data showed that the AUC based
on biopsy was 0.695, that is, the diagnosis based on bi-
opsy alone was not consistent with the gold standard.
Our data showed the accuracy rate of the diagnosis
based on biopsy was a mere 44% compared with ER-
specimens. The discrepancy between the diagnoses be-
tween biopsy and the ER-specimens can be explained
as follows. First, the biopsy tissue was a small piece of
the mucosa. Although it may include the muscularis
mucosa, it rarely contained the submucosa [12]. There-
fore, the depth of the lesions cannot be accurately deter-
mined based on the biopsy. Polymorphism of the precursor
was another important factor. Although the Lugol’s staining
and the narrow band imaging (NBI) determined the extent
of the lesions [13], the small tissue cannot depict the truedard (Endo: the endoscopy diagnosis; Bx: the diagnosis based on
Figure 3 The ROC of the Paris classification and the EUS compared with the gold standard in the staging (Paris: the Paris classification,
EUS: endo-ultrasonography).
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biopsy specimens affected the diagnosis of the lesion. If the
biopsy specimens were not flat, the specimens shrunk
with fixation, dehydration and embedding, resulting in
poor orientation of the lesions, and thereby affecting the
final diagnosis. Fourth, the subjective interpretation of the
criteria among the inter-observers variation in precursor
based on the biopsy have been a vexing issue for patholo-
gists and clinicians, for a definitive diagnosis [14].
Our data showed that the AUC of the diagnosis based
on the endoscopy and Paris classification were 0.735 and
0.728, respectively. The diagnostic consistency was better
than the consistency based on the biopsy alone. The two
approaches were based on endoscopic appearance using
the chromoendoscopy, such as the Lugol’s staining. Lugol’s
staining demonstrated the borderline and the stain grade,
while the Paris classification distinguished the invasive
from noninvasive lesion. It was reported that the “protrud-
ing” (type 0-I) and “excavated” (type 0-III) lesions were as-
sociated with higher risk of the submucosa invasion (70%)and lymph nodal metastases (30%) [3]. We used the Paris
classification as the indication for the choice of ER. The
invasion or non-invasion of the lesion should also com-
bined with the magnifying endoscopy.
According to the follow-up data from the high-risk area,
the rate of progression to esophageal SCC differs signifi-
cantly among LGIN (5.3% at 3 years follow-up), MGIN
(26.7%) and HGIN (65.2%) [15,16]. Therefore, the lesions
diagnosed as MGIN were also diagnosed by the ER.
Endoscopy and the Paris classification enable the right
choice of treatment. In our study, we adopted the worse
outcome as the diagnostic strategy to design our treatment
in the event of a discrepancy between endoscopy and bi-
opsy. If the diagnosis based on endoscopy was HGIN and
the pathological diagnosis based on the forceps biopsy was
LGIN, the treatment should be discussed with the pa-
tients. The pre-ER diagnosis should combined these two
diagnoses. The lesions diagnosed as HGIN should be
examined using an ultrasonic probe to determine the
invasive depth of the lesions. Nearly 45% (53/118) of the
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standard. The final treatment, such as the ER or esopha-
gectomy, should follow the NCCN principles based on the
pre-ER system diagnosis.
Using the EUS, the diagnostic accuracy for superficial
esophageal carcinoma reached 93%, to differentiate mu-
cosal from submucosal [17]. The 20 MHz probe showed
the esophageal layers distinctly, with lesions invading the
mucosa or submucosa scanned objectively [18]. Our data
showed that the AUCs of the diagnosis based on the EUS
and the Paris classification were 0.683 and 0.728 for sta-
ging, respectively, suggesting that the EUS and the Paris
classification examined the invasive depth of the lesions
objectively and enabled the choice of the treatment, com-
bined with biopsy. However, 6.7%-35.2% of the early inva-
sive esophageal cancers were associated with lymph node
metastasis [19]. Using the EUS to evaluate the lesions,
a false negative lymph node metastasis is a possibility,
whereas T staging of superficial esophageal cancer was
associated with 82.3% diagnostic accuracy [20]. Com-
puted tomography and convex ultrasonography should
be performed before ER to assess lymph node metasta-
sis. During the EUS operational procedure, there was
“upgrade” or “downgrade” rate. The reasons were that:
(1) There was different appearance of the lesions and
the different image in the EUS picture. When we used
the probe to exam the depth of the lesion, there was
bias because of this; (2) There was inflammation in the
lesion, and the invasion depth affected; (3) There was
minute invasion in the lesion and it was difficult to be
tested in the EUS.
ER was considered more precise than the EUS with re-
gard to the depth of invasion. Our data showed that the
AUC of the pre-ER diagnosis was 0.968. No significant dif-
ference was observed with the AUC of the diagnosis based
on ER, 0.971. Data showed that endoscopic diagnosis using
the Lugol’s staining, Paris classification, EUS and biopsy
were all needed before the ER, to arrive at an appropriate
choice of treatments in early esophageal cancer. Similar
approach is required for precancerous lesions using ER,
ablation or esophagectomy. The pre-ER system was more
important in the choice of the treatment in the absence of
ER specimens, including the RFA and PDT indicated for
the superficial esophageal precursor.
We tried to improve the diagnosis criteria by adding the
grading of the endoscopic appearance of the lesions after
Lugol’s iodine staining (based on the intensity of the lack
of staining and the margin characteristics of the lesion),
and by adding the stage criteria based on the Paris Classi-
fication and EUS findings. We concluded that the pre-ER
system can estimate lesion histology and stage as accur-
ately as post-ER by combining data from the endoscopic
appearance and biopsy diagnosis. And the most important
were that the use of the EUS for the stage and the Parisclassification for the including criteria. The weakness of
this study was that the study on the endoscopic appear-
ance of the lesion after the lugol’s staining was mainly
from China, and there was also no other study on it. In
this study, we want to share the experience in the lugol’s
for the diagnosis in the esophageal precursor.
In our study, we improve the diagnosis on these criteria
by adding (1) a grading of the endoscopic appearance of
the lesions after Lugol’s iodine staining (based on the in-
tensity of the lack of staining and the margin characteris-
tics of the lesion), and (2) the choice criteria for the ER
based on the Paris Classification and EUS findings. The re-
sults showed that it can estimate lesion histology and stage
as accurately pre-ER as post-ER by combining data from
endoscopic grading of the Lugol’s unstained lesions,
macroscopic appearance of the lesions by the Paris
Classification, EUS findings, and biopsy diagnoses. In
summary, the lesions which were diagnosed as early
cancer or precancerous lesions a endoscopically should
be re-diagnosed, based on a combination of the endoscopic
diagnosis, the Paris classification, the EUS and the biopsy.
The diagnostic accuracy of pre-ER system was comparable
to ER, which was important for the ablation.
Conclusion
In this study, we compared the diagnostic concordance
of this pre-ER system and ER histological diagnosis with
the gold standard in superficial esophageal precursor
and to evaluate the accuracies. The result was inspiring
that the system had the same accuracy with the ER spe-
cimen, and could make up the insufficient of the ER in the
diagnosis for the lesions and help to select treatment for
the superficial esophageal precursor.
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